Elevance Health, Inc. (NYSE: ELV) — The #2 Managed-Care Franchise on the Clearance Rack

Report date: 2026-06-13 Price reference: ~$404.07 (close 2026-06-12) · ~217M diluted shares · Market cap ~$88B · Total debt ~$32.0B · Cash & equiv ~$9.5B · Net debt ~$22.5B · EV ~$110B Sector: Health Care — Managed Care / Health Insurance & Services (GICS: Managed Health Care) Fiscal year: December · CIK: 0001156039 · HQ: Indianapolis, Indiana

This is independent fundamental research and general information, not investment advice. With the single, explicitly-labeled exception of the “Claude’s Take” block immediately below, it contains no buy/sell recommendation and no price target; the body of the analysis discusses valuation only as embedded expectations and scenarios.

⚡ Claude’s Take

This block is the author’s own independent, subjective opinion. It is general information and not investment advice. Everything below it is the analysis proper and deliberately carries no position or price target.

Verdict: ACCUMULATE on weakness — a cheap, washed-out #2 managed-care franchise with a far cleaner legal profile than the leader, where the earnings trough is unusually well-marked and the price already discounts a lot of the damage. Constructive below ~$400, with the real margin of safety in the high-$300s. Conviction: medium.

Elevance is the second-largest US health insurer (~45.2M medical members) and the largest Blue Cross Blue Shield licensee — the exclusive Blue brand across 14 states, a genuinely durable local-scale + brand + regulatory-license moat in commercial that the melting-managed-care multiple is undervaluing. The franchise has been dragged through a real, two-year earnings reset: the consolidated benefit-expense ratio (MLR) blew out +300bp from 87.0% (FY23) to 90.0% (FY25) on post-redetermination ACA morbidity and elevated Medicaid acuity, and adjusted EPS has fallen ~$33 (FY24) → $30.29 (FY25) → a guided ≥$26.75 for FY26. But three things separate ELV from a falling knife. First, the trough is visible and management is putting numbers on it: Q1-2026 beat (adjusted EPS $12.58, MLR 86.8%), management explicitly calls 2026 “the trough year,” and guides a return to ≥12% adjusted-EPS growth in 2027 off a clean ~$25.75 base (~$28.85), with MA repositioned to a ≥2% margin and Medicaid rates grinding toward trend. Second — the single most persuasive tell — CEO Gail Boudreaux bought ~$2.4M of stock in the open market at ~$286 in July 2025, with two directors adding ~$1.2M; rare, discretionary, conviction buying into the decline by the people with the best information (an echo of the UNH insider cluster). Third, ELV is legally clean relative to UNH — no criminal DOJ Medicare-coding probe, a more commercial/Blue-weighted book (~45% low-risk fee-based ASO) that is far less dependent on the MA risk-coding arbitrage now under attack. At ~$404 — ~13x FY25 adjusted EPS, ~15x the FY26 trough guide, P/S in the 16th percentile and P/B in the 35th percentile of its own 10-year history — the market is underwriting a broken compounder, not the partial recovery management is steering toward.

What keeps this an accumulate-on-weakness rather than a table-pounding BUY is that the bears own real evidence, not just narrative. Earnings quality is genuinely deteriorating: operating cash flow has collapsed from ~$8.1B (FY23) to $4.3B (FY25) — CFO/NI of just 0.76x — on a $2.5B government/premium receivable build, so reported profit is increasingly “on paper.” The Carelon “diversification engine” is ~75% captive internal revenue and consumers served fell 9% in FY25 — it is more transfer-pricing optics than an independent third-party franchise. Goodwill + intangibles equal ~90% of equity, so any Carelon impairment would gut book value. And the FY26 GAAP-to-adjusted gap has ballooned to a record ~$6.90/share (GAAP guide cut to ≥$19.85 in June 2026 even as adjusted held), which deserves skepticism. The framing is contrarian/cyclical-value with a quality caveat: you are buying a real franchise at a real discount in a real trough, but one whose cash conversion must re-prove itself. Flips bullish on two consecutive quarters of MLR improvement with CFO/NI recovering back toward 1.0x. Flips bearish on a third straight guidance reset (2026 not the trough), CFO conversion staying sub-0.8x, or an ACA/Medicaid morbidity miss. Catchy tag: “The #2 managed-care franchise on the clearance rack — cheaper and legally cleaner than the leader, if the trough holds and the cash shows up.”

1. Executive Summary

Elevance Health is the second-largest health-benefits company in the United States by membership, serving ~45.2M medical members as of 12/31/2025 and generating FY2025 revenue of $199.1B (+12.5% YoY). It is the largest single licensee of the Blue Cross Blue Shield brand, holding the exclusive Blue license in 14 states (its legacy Anthem/WellPoint footprint — California, New York, much of the Midwest and Southeast). The company reorganized in 2022 from “Anthem” to “Elevance Health” to signal a pivot from pure insurance toward a vertically-integrated health-services model built around its Carelon platform (PBM + care delivery + services). It reports in four segments: Health Benefits (the insurance engine, ~85% of segment operating gain historically), CarelonRx (pharmacy benefit management), Carelon Services (value-based care delivery, behavioral, home/community services), and Corporate & Other.

The franchise is strong; the last two years were a genuine earnings down-cycle. Revenue grew every year of the period (+44% cumulatively FY21→FY25), but operating income peaked at $8.50B in FY2023 and fell to $7.20B in FY2025, and net income slipped to $5.66B. GAAP diluted EPS held roughly flat at ~$25 only because buybacks shrank the share count from 246.8M to 224.6M and a discrete FY2025 tax benefit (15.6% effective rate) masked deeper operating deterioration. On the company’s preferred “adjusted” basis the decline is undisguised: adjusted diluted EPS fell from ~$33.04 (FY24) to $30.29 (FY25), and is guided to “at least $26.75” for FY2026 — a third consecutive down-step.

The cause is concentrated and identifiable: the medical loss ratio. The consolidated benefit-expense ratio rose from 87.0% (FY23) → 88.5% (FY24) → 90.0% (FY25), a +300bp swing on ~$165B of premium ≈ ~$4.9B of pre-tax gross-margin headwind. The damage is concentrated in two government-adjacent books: ACA/Individual (the remaining post-redetermination risk pool is sicker, and enhanced premium subsidies expired at end-2025) and Medicaid (acuity rose as ~2M lower-cost members rolled off in redeterminations while state rates lagged medical-cost trend). Health Benefits operating margin compressed from 4.6% to 2.5% in two years.

Recovery evidence is accumulating. Q1-2026 adjusted EPS of $12.58 beat, the quarter’s MLR was 86.8%, management raised FY2026 adjusted guidance to ≥$26.75, reaffirmed Medicare Advantage’s path to a ≥2% operating margin, and stated explicitly that 2026 is the trough year with ≥12% adjusted-EPS growth resuming in 2027 off a ~$25.75 baseline. The CY2027 CMS rate notice was modestly favorable. And the strongest signal is behavioral: CEO Boudreaux and two directors bought stock in the open market in 2025–26 — rare, discretionary purchases into the decline.

But earnings quality is the honest bear case, and it is real. Operating cash flow fell from ~$8.1B (FY23) to $4.3B (FY25) — a CFO/NI ratio of just 0.76x — driven by a $2.5B build in premium/government receivables plus a $666M BCBS antitrust-settlement cash payment. The Carelon growth story is ~75% captive internal revenue and saw consumers served fall 9%. Goodwill + intangibles equal ~90% of book equity. And the FY26 GAAP-to-adjusted reconciliation has ballooned to a record ~$6.90/share. These are not fatal, but they mean the “recovery” must convert to cash before it is believed.

Valuation says cheap-vs-own-history, fair-vs-normalized. At ~$404 ELV trades at ~13x FY2025 adjusted EPS, ~15x the FY2026 trough guide, ~20x depressed GAAP EPS, 0.45x sales (16th percentile of its own 10-year range), 2.0x book (35th percentile), and a ~2.0% dividend yield with a ~3% buyback. The composite own-history valuation percentile is ~39 — i.e., below its own median. The market is pricing a partial earnings recovery toward the high-$20s/low-$30s adjusted EPS with no quality re-rating. The payoff is more symmetric than UNH’s: ELV lacks the criminal-DOJ tail, but it also lacks UNH’s vertical-integration scale and carries its own cash-conversion question.

Bottom line for the committee: a structurally above-average #2 franchise — the dominant Blue licensee with a genuinely diversified, partly low-risk book — in a well-marked cyclical trough, at a washed-out valuation, with a cleaner legal profile than the sector leader and an insider-buying vote of confidence, offset by a real and unresolved deterioration in cash conversion that the recovery thesis must answer. The single most important open question is whether 2026 is truly the trough and whether the recovering earnings convert to cash.

2. Business Overview

Elevance Health operates as a diversified health-benefits company organized, since the 2023 segment realignment, into four reportable segments. FY2025 consolidated operating revenue was $197,584M (total revenue including investment income $199,125M), with ~96,000 employees.

2.1 The four segments — what they do and how they earn

(1) Health Benefits — the risk-bearing and fee-based insurer. FY2025 operating revenue $167,094M, operating gain $4,158M, operating margin 2.5% (FACT, FY2025 10-K, Note 20). This is the core franchise: it sells health plans across Individual/ACA, Employer Group (risk-based and fee-based/ASO), BlueCard (host-plan servicing for other Blues’ members traveling in ELV territory), Medicare (Advantage + Supplement), Medicaid, and the Federal Employee Program (FEP). It earns premium and bears medical risk on its risk-based book, and earns administrative fees (no medical risk) on its self-funded/ASO book. Health Benefits operating gain fell 33% YoY (from $6,243M) and is down ~40% from the FY2023 peak of $6,888M — the entire story of the earnings decline sits here.

By line of business, Health Benefits FY2025 operating revenue: Commercial $50,401M (of which Individual/ACA $9,295M), Medicare $44,752M (+21.6% YoY on the CareBridge/MA growth), Medicaid $56,620M (+9.0% on rate, despite member losses), FEP $15,321M.

(2) CarelonRx — the pharmacy benefit manager. FY2025 operating revenue $43,400M (+20.7%), operating gain $2,418M, operating margin 5.6% (FACT, Note 20). Home delivery, specialty pharmacy, formulary management, and rebate negotiation. It serves ELV’s own health plans and external clients. Critically, CarelonRx delegates its core PBM claims-processing operations to CVS Caremark through 12/31/2027 — a material third-party dependency and a contract that must be renewed or in-sourced.

(3) Carelon Services — value-based care delivery and services. FY2025 operating revenue $28,316M (+57.7%), operating gain $960M, operating margin 3.4% (FACT, Note 20). This is the “payvider” build-out — Carelon Health (value-based primary/home care), CareBridge (long-term services & supports for Medicaid/dual-eligibles, acquired Dec 2024), Paragon (infusion), and Carelon Insights (analytics, behavioral health, post-acute management). The 57.7% reported growth is overwhelmingly acquisition (CareBridge) and gross-basis capitation accounting, not organic volume.

(4) Corporate & Other. FY2025 operating revenue $463M, operating loss $(337)M — sub-threshold businesses and unallocated corporate costs (FY2024’s $(1,270)M loss carried the $666M BCBS settlement accrual).

2.2 Revenue composition and the Carelon captive flywheel

FY2025 revenue is ~83% premium (risk-bearing). The vertical-integration flywheel is large and measurable: intersegment eliminations were $41,689M in FY2025 (up 42% from $29,302M in FY2024) — ELV routing pharmacy and care spend through its own Carelon subsidiaries. Of CarelonRx’s $43.4B revenue, only ~56% is external ($24.5B); of Carelon Services’ $28.3B, only ~25% is external ($7.1B — 75% captive). This is the same flywheel UNH runs with Optum, at roughly one-quarter the scale and earlier in its build. (See for the interpretation: this is real margin capture, but it inflates the apparent “diversification.”)

2.3 Membership (FACT, 10-K, 12/31, thousands)

The mix is materially healthier than a pure-play MA insurer’s: ~27.1M commercial fee-based (ASO) members carry no medical risk — 45.5% of the book — a structural diversification Humana entirely lacks. Medicaid fell ~2.0M (−19%) from the FY2023 peak through redeterminations, the dominant volume story.

Verdict: A genuinely diversified, scaled #2 health-benefits franchise — the dominant Blue licensee, with a large, low-risk fee-based commercial book and a growing (if heavily captive) Carelon services arm. The structure is more defensive than a pure-play insurer’s, but ~83% of revenue is still risk premium, and FY2025 proved the diversification did not insulate earnings — the MLR blowout in ACA/Medicaid swamped everything.

3. Industry Dynamics

3.1 Structure, size, and profit pools

US managed care is a ~$1.5T+ premium industry across three profit pools with very different economics:

• Medicare Advantage — highest-margin, fastest-growing pool; MA penetration ~54% of eligibles and climbing toward ~64% by 2034 (KFF). The sector’s best secular demand story — and precisely why CMS is reclaiming margin via the V28 risk model and tighter rates. ELV is a distant #5 in MA (~2.2M MA members vs UNH ~8.4M, Humana ~6M) — under-indexed to the richest pool, which cuts both ways (less upside, but also less exposure to the MA-coding crackdown).
• Medicaid — large, low-margin, state-funded, currently squeezed by post-redetermination acuity and rate inadequacy. ELV is a top-tier Medicaid MCO (~8.5M members) — over-indexed to the most pressured pool right now.
• Commercial — mature, mid-single-digit growth, increasingly self-funded (fee-based). This is ELV’s relative strength: as the largest Blue licensee it has dominant local commercial share in its 14 states, where the Blue brand and provider-network depth are a genuine local-scale advantage.

3.2 Competitive intensity — national oligopoly, deep local concentration

The “Big 5” national managed-care players are UNH, Elevance, CVS/Aetna, Cigna, Humana, plus Centene (Medicaid/ACA) and Molina (Medicaid). Differentiation: UNH (Optum payvider at unmatched national scale); Elevance (Blue-brand commercial dominance in 14 states + Carelon, building); CVS/Aetna (retail + Caremark PBM); Cigna (Evernorth/Express Scripts PBM, thin MA); Humana (MA pure-play); Centene/Molina (Medicaid). ELV’s competitive position is strongest in commercial (Blue local scale) and weakest in MA (sub-scale national #5). In its Blue states, ELV typically holds #1 or #2 commercial share — a local economies-of-scale + brand moat that the others cannot replicate because the Blue license is exclusive and geographically carved.

3.3 The PBM structure

The Big 3 PBMs control ~80% of US scripts: Caremark (CVS), Express Scripts (Cigna), OptumRx (UNH). CarelonRx is a distant #4 and, tellingly, delegates core operations to CVS Caremark through 2027 — i.e., ELV does not yet have a fully independent PBM at scale. This is both a dependency risk and an in-sourcing opportunity (ELV is building toward owning more of the stack).

3.4 Regulation — CMS as monopsony, plus the ACA subsidy cliff

Insurer pricing power in government programs is near zero — CMS and the states set rates, write the risk models, run quality programs, and audit. The machinery currently relevant to ELV:

• Medicaid redeterminations & rate adequacy — the dominant FY2024–26 headwind. States completed redeterminations by 12/31/2025; the remaining pool is sicker, and state rate increases (mid-single-digit) have lagged medical-cost trend, producing a negative Medicaid margin (ELV guides ~−1.75% for 2026). The OBBBA (signed 7/4/2025) mandates more frequent redeterminations and work requirements from 2027–28 — implying continued Medicaid attrition.
• ACA enhanced-subsidy expiration (“the subsidy cliff”) — the enhanced premium tax credits from ARPA/IRA expired at the end of 2025, raising net premiums for ~20M marketplace enrollees and driving adverse selection (healthier members drop, the remaining pool gets sicker). ELV priced FY2026 prudently for this and is seeing a favorable shift toward bronze plans, but the morbidity of the residual pool is the key 2026 uncertainty.
• V28 MA risk model & CMS rate cycle — punitive in 2025–26, but the CY2027 final notice was modestly favorable. ELV’s small MA book limits both the damage and the recovery.
• PBM scrutiny (FTC) — bipartisan pressure on PBM rebate economics; less acute for sub-scale CarelonRx than for the Big 3.

3.5 Marathon capital-cycle read

This is a classic late-bust / early-recovery across managed care. Capital and benefit-generosity over-flooded MA and Medicaid in 2020–23; supply discipline (county exits, benefit cuts, MA repositioning) is now restoring survivor margins. ELV is deliberately shedding unprofitable membership (Medicaid attrition, MA repositioning, disciplined commercial pricing). Marathon’s caveat bites: the same monopsony (CMS/states) that caused the bust can reclaim the upturn via rate notices. But ELV’s commercial book is outside this government cycle — a stabilizer the pure-plays lack.

Verdict: Structurally mixed-to-above-average for ELV specifically. The MA secular tailwind is captured by a buyer harvesting margin, and Medicaid is in a rate-inadequacy trough — both pressuring ELV now. But ELV’s distinctive asset is the commercial Blue franchise, a local-scale + brand + exclusive-license moat outside the government-margin cycle, plus a low-risk fee-based book that earns fees regardless of medical trend. The industry is “government margin in a reset, commercial as the ballast — and ELV is the most commercial-weighted of the big risk-bearers.”

4. Competitive Position / Moat

4.1 Naming the moat (Greenwald taxonomy)

ELV’s moat is local economies of scale + brand/regulatory intangibles in commercial (the Blue license), layered with a building cost-advantage/captive-demand engine in Carelon. It is real but narrower and shallower than UNH’s national payvider moat.

• The Blue Cross Blue Shield license — the genuine, durable moat. ELV holds the exclusive right to the Blue brand across 14 states. Within those states it has dominant commercial share, the deepest provider networks (decades of contracting), and the strongest brand recognition — a textbook local economies-of-scale advantage (fixed network/brand costs spread over the largest local membership base) reinforced by an intangible/regulatory barrier (the license is exclusive and cannot be replicated by a competitor in-territory). This is why ELV’s commercial book is structurally more defensible than its MA or Medicaid books. The BlueCard system (national reciprocity among Blues) adds a network effect at the system level that benefits all Blue licensees.
• Economies of scale: real but #2. ~45M members is national scale, but below UNH’s ~50M and without UNH’s vertical depth. Scale shows up in provider-contracting leverage and fixed-cost absorption, but ELV is the price-taker to UNH’s price-setter nationally.
• Carelon (cost advantage + captive demand): building, not yet a moat. Owning the PBM and the care-delivery arm lets ELV capture the medical-cost dollar internally — the same logic as Optum. But CarelonRx still delegates to CVS, Carelon Services is 75% captive with falling consumers served, and the segment margins (3–6%) are below the insurance book it feeds. This is a capability under construction, not yet a durable barrier.
• Switching costs: weak at the member level (MA/Medicaid/ACA members re-shop annually for free), moderate in fee-based commercial (employer ASO relationships are sticky, multi-year, integration-heavy).
• Network effects: only at the BlueCard/system level, not firm-specific.

4.2 Does the moat show up in returns — and is it durable?

The honest answer: the moat shows up, but the returns are currently depressed and the cash isn’t fully converting. ROE on FY2025 net income of $5.66B against ~$43.9B equity is ~13% — but that equity is ~90% goodwill/intangibles, so ROE on tangible equity is far higher (tangible equity ~$4.3B) and largely uninformative. ROIC (NOPAT ~$5.5–6B against ~$55B invested capital incl. debt) is ~10–11% — above the ~7–8% cost of capital, but compressed from the ~14% of FY2023. The Greenwald test — does the moat tie to a financial outcome that would deteriorate without it? — passes for the commercial Blue book (its margins are the most stable and would not exist without the license/local scale) and is inconclusive for Carelon (margins are thin and the “growth” is internal). Market-share stability: ELV has held its commercial Blue share for decades — the hallmark of a real local moat — while its MA share is small and contested.

Verdict: A real but narrower moat than the sector leader’s, anchored in the commercial Blue franchise. Durable local-scale + exclusive-brand advantage in 14 states (the part the cyclical multiple ignores); a sub-scale, contested position in MA and PBM; and a Carelon “payvider” capability that is strategically sound but not yet a financial moat. ELV is a structurally advantaged #2, not a wide-moat compounder.

5. Growth History and Forward Opportunities

5.1 The historical record — revenue growth, earnings reset

Revenue compounded ~9.5%/yr (FY21→FY25), driven by Medicaid expansion, MA growth, Carelon acquisitions, and rate. But the earnings engine peaked in FY2023 and has reset down — operating income −15% from the peak, adjusted EPS −8% from the FY24 peak with a further step down guided for FY26. The growth was real on the top line, hollow on the bottom line over the last two years — the definition of low-quality growth in a risk-bearing insurer when medical-cost trend outruns pricing.

5.2 Organic vs. acquired

A meaningful slice of recent growth is acquired: CareBridge (~$2.7B, Dec 2024) drove most of Carelon Services’ 58% revenue jump; BioPlus (Feb 2023), Paragon (Mar 2024), and Kroger Specialty Pharmacy built CarelonRx. Carelon Services’ consumers served fell 9% in FY2025 — confirming the reported growth is acquisition + gross-capitation accounting, not organic volume. Organic medical membership actually declined (−1.1% in FY25, −2.3% in FY24) on Medicaid redeterminations.

5.3 Forward opportunities

• The 2027 recovery — management guides ≥12% adjusted-EPS growth off a ~$25.75 FY26 base (~$28.85 in 2027), as MA reaches ≥2% margin, Medicaid rates catch up to trend, and the ACA pool stabilizes. This is the central bull driver.
• Carelon scaling — growing external (third-party) Carelon revenue, in-sourcing the PBM from CVS post-2027, and expanding value-based/LTSS care. The genuine long-term margin-mix opportunity, if it converts to real third-party share.
• Commercial share & integrated medical-pharmacy — leveraging the Blue franchise to sell integrated CarelonRx + Health Benefits to employers; ELV cites a “strong 2026 selling season” and national-account wins.
• AI/operating-cost leverage — the operating-expense ratio improved to 10.5% (Q1-26) on automation; a real but incremental lever.

Verdict: Low-quality recent growth (top-line up, earnings reset down, much of it acquired and captive), with a credible — but unproven — recovery and a genuine long-term Carelon mix-shift opportunity. The forward case rests on management’s “2026 is the trough” claim holding.

6. Financial Quality

6.1 Margins and the MLR — the whole story

The consolidated benefit-expense ratio (MLR) deteriorated +300bp in two years: 87.0% (FY23) → 88.5% (FY24) → 90.0% (FY25) (FACT, 10-K). On ~$165B of premium, that is ~$4.9B of pre-tax gross-margin headwind — the dominant driver of the earnings reset, concentrated in ACA (post-redetermination morbidity) and Medicaid (acuity). The offsetting good news: the operating-expense (SG&A) ratio improved from 11.8% → 11.4% → 10.6% on operating leverage and cost discipline — but a 80bp SG&A improvement cannot offset a 300bp MLR blowout. Health Benefits operating margin fell from 4.6% to 2.5%.

6.2 The cash-conversion red flag — the cleanest bear datapoint

Operating cash flow collapsed from $8.06B (FY23) to $5.81B (FY24) to $4.29B (FY25) — a CFO/NI ratio of just ~0.76x in FY2025 (management concedes “approximately 0.8x”). The drivers (cash-flow statement, FY25 10-K):

• Receivables used $2,526M of cash (vs $683M in FY24) — premium receivables jumped $8.0B→$10.1B as government/premium timing (Medicaid rate true-ups, CMS/ACA risk-adjustment, deferred premium recognition pending state rate approvals) ballooned. This is the item to watch: if these receivables don’t convert to cash, the reported earnings are increasingly accrual-only.
• The $666M BCBS antitrust-settlement cash payment (accrued FY24, paid Sept 2025) — a one-time CFO drag.
• Days-in-claims-payable rose to 46.6 (Q1-26, +5.3 sequential) — a modest reserve-build cushion, but also a sign of slower claim run-out.

Management guides FY2026 CFO to “at least $5.5B” (inclusive of potential cash payments for the “CMS matter”), implying a partial recovery in conversion. The recovery thesis is not validated until CFO/NI moves back toward 1.0x.

6.3 Quality of earnings — the GAAP-to-adjusted gap

GAAP diluted EPS held at ~$25 partly on a discrete FY2025 tax benefit (15.6% effective rate vs 24.5% in FY24) from an internal subsidiary restructuring — worth ~$3.50–4.00/share and not repeatable. More concerning forward: the FY2026 GAAP-to-adjusted gap has ballooned to ~$6.90/share (GAAP guide cut to ≥$19.85 in June 2026 on rising “unfavorable items,” even as adjusted held at ≥$26.75) — the largest add-back ELV has ever carried, and a quality-of-guidance flag worth probing. Adjusted EPS excludes intangible amortization ($628M in FY25), net investment losses, and “business-optimization” charges.

6.4 Balance sheet

Sound investment-grade: total debt $32.0B, debt-to-capital 42.1% (covenant max 60%), cash & equivalents $9.5B, total cash + investments $37.2B, senior ratings A−/BBB+/Baa2. Statutory capital ~$22.6B is ~2.5x the RBC minimum. But equity ($43.9B) is ~90% goodwill + intangibles ($39.5B) — tangible equity is only ~$4.3B, so any Carelon impairment would gut book value. Net investment income ($2.19B, +7%) is a genuine tailwind from higher rates.

6.5 Segment economics — where the money is actually made and lost

The four-segment view reveals an important truth the consolidated MLR obscures: the profit is increasingly bifurcated between a shrinking-margin insurance book and a growing-but-thin services book. FY2025 segment operating gains: Health Benefits $4,158M (down from $6,888M peak), CarelonRx $2,418M, Carelon Services $960M, Corporate $(337)M. Carelon (RX + Services) now contributes ~47% of total segment operating gain ($3,378M of $7,199M), up from ~37% a year earlier — but this is partly an arithmetic shift (the numerator grew modestly while the Health Benefits denominator collapsed), not solely a structural diversification win. The uncomfortable read: ELV’s profit mix is “improving” largely because its core insurance margin is falling, not because Carelon is independently surging. CarelonRx’s 5.6% margin and Carelon Services’ 3.4% margin are below a healthy Health Benefits margin (4.6% at the FY23 peak), so a permanent mix-shift toward Carelon, absent margin expansion there, would structurally lower blended profitability — unless Carelon’s external (third-party) franchise scales and its margins widen. That is the crux of the long-term Carelon bet, and the FY2025 data (consumers served −9%, 75% captive) does not yet confirm it.

Net investment income ($2.19B, +7%) deserves emphasis as a quality offset: in a thin-margin insurer, the float (medical-claims-payable $17.1B + reserves + statutory capital invested in a $37B portfolio) generates real, recurring earnings that are more durable than the underwriting margin and benefit from higher rates. Roughly $2.2B of pre-tax investment income against $7.2B operating income means ~30% of pre-tax profit is effectively investment-driven — a Buffett-style insurance-float dynamic that the market under-credits in a low-multiple managed-care name, but also a reminder that underwriting itself is barely profitable right now.

Verdict: Economics did NOT improve with scale over the last two years — they deteriorated, badly, on the MLR, and cash conversion deteriorated even faster. The balance sheet is sound and statutory capital ample, but the heavy intangible loading and the CFO/NI collapse are real quality flags. This is a cyclically-depressed, accrual-rich earnings stream that must re-prove its cash conversion.

7. Capital Allocation

7.1 The framework

Buybacks: steady ~$2–3B/yr, fully FCF-funded; FY25 repurchased 7.4M shares for $2,605M, shrinking the count ~9% over four years; $6.7B remaining authorization; FY26 guided to ≥$2.3B (Q1-26: 3.7M shares for $1.1B at ~$300). Executed at reasonable-to-good prices (the 2025 buybacks were at $280–320, near the lows) — better timing than UNH’s peak-priced repurchases.

Dividend: $1.71/qtr in FY25, raised to $1.72/qtr for 2026 ($6.88/yr); ~22% adjusted payout, well-covered, ~5%/yr growth. Conservative and disciplined. ~$4.1B total capital returned in FY2025.

M&A — the Carelon roll-up: CareBridge (~$2.7B, Dec 2024, LTSS), Paragon (Mar 2024, infusion), BioPlus (Feb 2023, specialty pharmacy), Kroger Specialty Pharmacy. Strategically coherent (vertical integration into value-based care and specialty), prices not visibly egregious, and FY2025 was a deliberate digestion pause ($88M). But it has built goodwill+intangibles to ~90% of equity.

7.2 Incentives and insider behavior — the mixed governance read

The weak link is incentive design. The annual bonus is 50% Adjusted Net Income / 20% Operating Revenue / 30% strategic initiatives; the long-term PSUs vest on Adjusted EPS + Operating Revenue over three years. There is no ROIC gate and no relative-TSR metric — both the bonus and the PSU reward exactly the metrics that buybacks and acquisitions mechanically inflate, with no return-on-capital discipline. Say-on-pay passed at only ~92% (soft for a large cap), and insiders own <0.4% of the company — thin alignment. CEO Boudreaux’s FY2025 total comp was $22.6M, base flat at $1.6M for three years.

The redeeming counter-signal is open-market buying. Against ELV’s history of essentially no insider buying, CEO Gail Boudreaux purchased ~8,500 shares (~$2.44M) in the open market on 2025-07-18 at ~$286–288, into the post-guidance-cut decline; director Susan DeVore added ~$375K (Aug 2025) and new director Steven Collis (ex-Cencora CEO) ~$870K (Mar 2026). These are rare, discretionary, conviction purchases by the best-informed insiders — the most persuasive bullish tell in the file, and a near-direct analogue to the UNH 2025 insider cluster.

7.3 Leadership

Boudreaux remains President & CEO (no transition, contrary to some speculation). The notable change is Carelon President Peter Haytaian departing (eff. May 2026, “family commitments”) amid the segment reshuffle (Felicia Norwood → Chief Health Benefits Officer) — losing the Carelon head during the reset is worth monitoring. The board added two independents (Collis, Schulman).

Verdict: Competent and disciplined on the surface — FCF-funded buybacks at good prices, a conservative growing dividend, a coherent and paused Carelon roll-up — but incentive-structurally biased toward the acquire-and-buyback flywheel with no ROIC/TSR gate, thin insider ownership, and softening say-on-pay. The CEO’s open-market buying is the offsetting vote of conviction. Net: above-average execution, below-average incentive design.

8. Changes and Headwinds — Last Two Years

• The MLR reset (FY24–25) — the defining change: +300bp benefit-ratio deterioration on ACA morbidity + Medicaid acuity, driving two consecutive guidance cuts (FY24 adjusted EPS “>$37.20” → “>$34.05”; FY26 adjusted resetting to ≥$26.75 off an original FY25 “>$34.15–34.85”).
• Medicaid redeterminations — ~2.0M members (−19%) rolled off FY23→FY25; the residual pool is sicker, state rates lag trend (−1.75% margin guide for 2026), and OBBBA mandates more frequent redeterminations from 2027–28.
• ACA subsidy cliff — enhanced premium tax credits expired end-2025; FY2026 carries adverse-selection risk, priced prudently (bronze shift helping).
• MA repositioning — selective market exits and product cuts to drive MA to a ≥2% margin in 2026; ELV is shrinking the unprofitable book deliberately.
• The “CMS matter” — an unquantified regulatory item with potential cash payments (factored into the ≥$5.5B FY26 CFO guide). Far smaller and less defined than UNH’s criminal DOJ probe, but a watch item.
• CareBridge acquisition (Dec 2024) — the largest recent deal, building the LTSS/home-care capability.
• Carelon leadership departure (Haytaian, May 2026) and segment reshuffle.
• The BCBS antitrust settlement ($2.8B industry settlement; ELV’s $666M cash paid Sept 2025) — resolved, but a cash drag.

Verdict: On balance these WEAKEN the near-term thesis but do not break the franchise. The MLR reset and government-program pressure are real and ongoing; the offset is deliberate margin-repair actions (MA repositioning, Medicaid rate advocacy, ACA prudence) plus a clean legal profile vs UNH. The thesis turns on whether the repair actions land in 2026 as management claims.

9. Risk Analysis

The dominant risks are cyclical/operational (MLR trend, cash conversion, government rate adequacy) rather than existential. Catastrophic loss is highly unlikely given the balance sheet. The asymmetric tail is a prolonged trough (no 2027 recovery) compounded by an impairment if Carelon underperforms.

10. Valuation Discussion — Embedded Expectations

10.1 Where the multiples sit

At ~$404 (~217M shares, ~$88B market cap, ~$110B EV):

The signal: ELV is cheap on sales and book versus its own history, mid-range on depressed earnings, and not expensive on normalized earnings. This is the classic profile of a cyclical at a trough — the P/E looks unremarkable because the “E” is depressed, while the asset/sales multiples flag the washout.

10.2 Peer cross-read

The sector peers all earned “HOLD” because they had already re-rated off their lows. ELV is distinctive in that it sits near its 52-week low (down from ~$550+ in 2024), not its recovery high — the cyclical-value entry the others no longer offer. ELV deserves a quality premium to CVS/CNC and trades at a discount to UNH; a 13–15x multiple on normalized earnings is the sector-appropriate range.

10.3 Embedded-expectations / scenario analysis

What the ~$404 price underwrites: roughly 14–15x a normalized adjusted-EPS power of ~$27–29 — i.e., a partial recovery toward (not beyond) the FY2027 guide, with no re-rating and no credit for the commercial-Blue franchise or Carelon mix-shift. The market is not pricing a clean return to the ~$33 FY24 peak earnings.

• Bear (~$300–340, ~−15–25%): 2026 is not the trough; a third guidance cut; CFO/NI stuck sub-0.8x; Medicaid/ACA worse than priced; normalized adjusted EPS resets toward ~$24 at a de-rated ~13x. A Carelon impairment would deepen this.
• Base (~$420–480): 2026 trough holds; 2027 adjusted EPS ~$29 (the ≥12%-growth guide); CFO conversion recovers toward 0.9–1.0x; market pays ~14–16x → ~$405–465, plus the ~5% shareholder yield while you wait.
• Bull (~$520–600): full recovery toward ~$33–35 adjusted EPS by 2028 as Medicaid rates normalize, ACA stabilizes, MA hits ≥2% and scales, Carelon converts to external growth, and the market re-rates the commercial franchise to ~16x → ~$530–560+. This was the ~$550 the stock traded at in 2024.

The skew is more symmetric than UNH’s (no criminal-DOJ left tail) but the base case requires the cash conversion to re-prove itself.

10.4 A normalized-earnings bridge

The valuation question reduces to one number: normalized adjusted EPS power. The bridge from the FY2026 trough to a normalized level:

• FY2026 baseline (ex-nonrecurring): ~$25.75 (the company’s stated 2027-growth base, stripping the ~$1 of nonrecurring Q1 investment income from the ≥$26.75 guide).
• + Medicaid margin normalization: Medicaid at −1.75% operating margin on ~$57B of revenue is ~$1.0B of pre-tax drag vs a normal ~+1.5–2% margin; closing even half that rate-to-trend gap adds ~$0.5B pre-tax ≈ ~$1.75/share after tax.
• + MA reaching/exceeding 2% margin and scaling: ~$0.50–1.00/share as the repositioned book matures.
• + ACA pool stabilization (post-cliff morbidity priced through): ~$0.50–1.00/share.
• + Carelon margin progression + buyback (~3%/yr): ~$1.50–2.00/share combined.
• = Normalized adjusted EPS ~$30–33 by FY2027–2028 — i.e., back toward (not above) the FY2024 peak.

At ~$404, the market pays ~13–13.5x that ~$30–33 normalized power — a discount to the 14–16x the franchise has historically commanded and to a fair sector multiple. Put differently, a reverse read: at a sector-normal 14.5x, ~$30–33 normalized EPS implies ~$435–480; at a recovery-bull 16x on ~$33, ~$528. The current price embeds roughly a partial recovery (to ~$29 at ~14x) with a haircut for the cash-conversion and Medicaid-rate uncertainty. The ~5% shareholder yield (2% dividend + ~3% buyback) is the carry while the normalization plays out.

The single biggest swing factor in this bridge is not earnings but the multiple the market is willing to pay — managed care de-rated sector-wide in 2024–25 from ~16–18x to ~12–15x as investors lost confidence in the predictability of medical-cost trend. A re-rating back toward the historical range, combined with the earnings recovery, is the bull’s double-barreled upside; a permanent de-rating (medical trend deemed structurally less forecastable) is the bear’s cap on it.

Verdict: Cheap versus its own history on sales/book, fairly-to-attractively valued on normalized earnings, pricing a partial recovery. The valuation pays you to wait (~5% shareholder yield) and offers genuine cyclical-recovery optionality, with the principal risk being that the trough is deeper or longer than management asserts.

11. Variant Perception

Consensus view: ELV is a structurally-pressured #2 insurer in a managed-care down-cycle; the Street is lukewarm (mean target ~$387, below the price), viewing it as a “show-me” recovery with Medicaid/ACA overhangs — though Mizuho (PT $465, Outperform) represents the constructive minority.

Strongest bull case: This is a real, dominant Blue-brand franchise at a washed-out price (P/S 16th percentile of own history), in a well-marked trough that management is steering out of (2026 = trough, ≥12% growth in 2027, MA to ≥2% margin), with a far cleaner legal profile than UNH and a CEO who bought $2.4M of stock at the lows. You’re paid ~5% to wait for a recovery the company is putting concrete numbers on.

Strongest bear case: The earnings are increasingly accrual-only (CFO/NI 0.76x, $2.5B receivable build), the “diversification” (Carelon) is 75% captive with falling consumers served, goodwill is 90% of equity, the GAAP-to-adjusted gap is a record ~$6.90, and management has now cut guidance two years running — “2026 is the trough” is exactly what they said about 2025. Government-program margin is structurally pressured (Medicaid rate inadequacy, ACA subsidy cliff, OBBBA), and ELV is over-indexed to the worst pool (Medicaid) and under-indexed to the best (MA).

The 3–5 assumptions that matter most:

1. Is 2026 actually the trough? (vs a third reset) — falsified by another guidance cut.
2. Does CFO/NI recover toward 1.0x? — falsified by FY26 CFO missing the ≥$5.5B guide / conversion staying sub-0.8x.
3. Do Medicaid rates close the gap to trend? — falsified by the −1.75% margin deepening.
4. Does the ACA residual pool stabilize as priced? — falsified by a back-half 2026 MLR miss.
5. Does Carelon convert to real external growth? — falsified by external Carelon revenue stalling and consumers-served continuing to fall.

What would falsify each side: Bull falsified by a third guidance cut or CFO staying broken; bear falsified by two consecutive quarters of MLR improvement with CFO/NI back toward 1.0x and the 2027 growth guide reaffirmed with detail.

12. Fact vs. Interpretation

13. Open Questions

1. Is 2026 genuinely the trough, or the third in a series of resets? The single most important question.
2. Why exactly did the FY26 GAAP-to-adjusted gap balloon to ~$6.90, and what are the “unfavorable items”? Quality-of-guidance concern.
3. What is the “CMS matter,” and what is the cash exposure? Unquantified in disclosures.
4. Will the $2.5B receivable build convert to cash in 2026, restoring CFO/NI?
5. What is ELV’s plan for the CVS PBM delegation expiring end-2027 — in-source or renew, and at what cost?
6. Is Carelon’s external (third-party) revenue actually growing, ex-acquisition and ex-capitation gross-up?
7. How sick is the residual ACA pool post-subsidy-cliff — and is the bronze shift enough?
8. What normalized Medicaid margin is achievable once rates catch trend — back to positive, or structurally thinner?

14. What Must Be True

Bull case — what must be true:

• 2026 prints as the trough: full-year adjusted EPS ≥$26.75 with no further cut, and the back-half MLR holds to the ~90.2% guide.
• 2027 delivers ≥12% adjusted-EPS growth (~$28.85+) as MA reaches ≥2% margin and Medicaid rates close the trend gap.
• CFO/NI recovers toward ~1.0x (FY26 CFO ≥$5.5B), proving the earnings are cash.
• The commercial Blue franchise holds share and margin, providing ballast outside the government cycle.
• Falsification test: A third consecutive guidance reset, OR FY2026 CFO missing ≥$5.5B with CFO/NI stuck below 0.8x. Either kills the “trough + cash recovery” thesis.

Bear case — what must be true:

• Government-program margin is structurally (not cyclically) impaired: Medicaid rate inadequacy persists, ACA morbidity overshoots pricing, OBBBA accelerates attrition.
• Cash conversion stays broken; the receivable build does not reverse; reported earnings remain accrual-rich.
• Carelon underperforms, raising goodwill-impairment risk against ~90%-of-equity intangibles.
• Falsification test: Two consecutive quarters of MLR improvement WITH CFO/NI recovering toward 1.0x, plus a detailed reaffirmation of the 2027 ≥12% growth guide. That would confirm the cyclical-recovery read and refute structural impairment.

15. Source Appendix

See ELV_source_appendix.md (Appendix B in the combined report) for the full source list. Primary sources: Elevance Health FY2025 10-K (filed 2026-02-06), FY2024 10-K, FY2021–FY2025 10-Ks; DEF 14A (2026-03-27); 8-Ks (guidance, leadership, buyback authorizations, 2024–2026); Form 4 insider filings (2024–2026); Q1-2026 / Q4-2025 earnings-call transcripts; SEC EDGAR XBRL financial concepts; public market-data feeds (valuation percentiles vs. own history); and public filings of managed-care peers (UnitedHealth, Humana, CVS Health, Cencora, McKesson) for cross-read.

APPENDIX A — Standard Diligence Questionnaire

Elevance Health, Inc. (NYSE: ELV) · Report date 2026-06-13 · Supplemental to the research memo.

General — What thoughtful questions have other investors asked?

The dominant investor questions on ELV cluster around: (1) Is 2026 the earnings trough, or the third in a series of guidance cuts? (2) Why has operating cash flow collapsed to 0.76x net income, and is the $2.5B receivable build a timing issue or an earnings-quality problem? (3) How sick is the residual ACA risk pool after the enhanced-subsidy cliff? (4) Will Medicaid rates ever catch up to medical-cost trend? (5) Is Carelon a real third-party growth engine or just internal transfer pricing? (6) What is the “CMS matter” and its cash exposure? The Q1-2026 call was dominated by Medicaid rate-adequacy, ACA bronze-plan mix, and Carelon-margin-progression questions.

Cyclicality & Earnings Nature

• Cyclical high or low? Decisively a cyclical low. Operating income peaked at $8.5B (FY23) and fell to $7.2B (FY25); adjusted EPS fell ~$33→$30.29→a guided ≥$26.75. Management explicitly calls 2026 “the trough year.” (Interpretation: the trough framing is a management hypothesis, not yet validated.)
• External environment or internal actions? Predominantly external (CMS/state rate inadequacy, Medicaid redetermination acuity, ACA subsidy-cliff morbidity, medical-cost trend) — the same forces that hit every managed-care peer in 2024–25. Internal actions (MA repositioning, Medicaid rate advocacy, ACA pricing discipline, cost-out) are the repair levers.
• Revenue stability? High and recurring at the top line (entitlement + multi-year employer/ASO contracts), but the risk-based premium book re-prices annually and members re-shop with no switching cost. The ~27M fee-based ASO members are the stickiest, lowest-volatility revenue.
• Outlook for products/services? Secular demand is strong (MA penetration → ~64% by 2034; aging demographics), but profit is captured by a monopsony buyer (CMS/states). Commercial is mature/stable; Carelon services is the growth adjacency.
• Market size — growing/shrinking, domestic/international? ~$1.5T+ US managed-care premium pool, growing mid-single-digit; 100% domestic. ELV’s addressable government pools are large but margin-pressured; its commercial Blue franchise is mature but defensible.

Business Quality & Competitive Moat

• Industry more or less competitive? Roughly stable national oligopoly (Big 5 + Centene/Molina); intensifying in MA (margin reset, county exits) and Medicaid (rate politics); ELV’s commercial Blue territory is structurally protected by the exclusive license.
• How profitable (ROIC/ROE)? ROE ~13% on FY25 net income (but equity is ~90% intangibles); ROIC ~10–11% (down from ~14% at the FY23 peak) — above ~7–8% cost of capital but compressed. Net margin ~2.8% (thin, typical of a risk insurer).
• Industry profitability / barriers? Moderate-to-good for incumbents; high barriers (capital/RBC requirements, network-contracting scale, regulatory licensing, Blue-brand exclusivity). Few competitors at national scale.
• Easily understood? Reasonably — it’s a premium-in, claims-out risk insurer plus a services arm; the complexity is in medical-cost-trend forecasting and segment/captive accounting.
• Undermined by foreign low-cost labor? No — domestic, regulated, network-and-license-based.
• Do brands matter? Yes — uniquely so here. The Blue Cross Blue Shield brand is a genuine intangible asset and the exclusive license is the core moat in commercial.
• Nature of competition? Price (premiums/bids), network breadth, MLR management, Stars/quality ratings, and benefit design — competed locally and by line of business.
• Customer switching costs? Low for individual members (annual re-shop); moderate for employer ASO accounts (integration, multi-year).

Financial Condition & Balance Sheet

• Assets not fully recognized? The Blue license / brand value and the in-territory provider networks are not on the balance sheet at economic value. The investment portfolio ($37B) is marked.
• Off-balance-sheet liabilities? Standard operating leases (ROU on-balance-sheet); medical-claims-payable ($17.1B) is on-balance-sheet; the BCBS settlement was accrued and paid. The “CMS matter” potential cash payment is an unquantified contingency.
• Accounting conservatism? Mixed. Reserve practices (days-in-claims-payable 46.6) appear adequate-to-conservative, but the record ~$6.90 GAAP-to-adjusted gap and the FY25 discrete tax benefit (15.6% rate) flatter the headline; the receivable build raises accrual-quality questions. (Interpretation: lean skeptical on the “adjusted” framing.)
• CapEx-hungry? No — asset-light; capex is modest (IT/facilities). The capital intensity is statutory/RBC capital (~$22.6B) and goodwill from M&A, not physical capex.

Capital Allocation & Management

• FCF generation & use? Normally ~$6–8B CFO, but depressed to $4.3B (FY25) on the receivable build. Used for: dividends (~$1.5B, ~22% payout), buybacks (~$2.6B, $6.7B authorized remaining), and M&A (Carelon). FY26 CFO guided ≥$5.5B.
• Philosophy? Balanced return-of-capital (buyback + growing dividend) plus strategic Carelon vertical-integration M&A; paused acquisitions in 2025 to digest.
• Significant acquisitions? CareBridge (~$2.7B, Dec 2024), Paragon (Mar 2024), BioPlus (Feb 2023), Kroger Specialty Pharmacy — building Carelon. Coherent, reasonably priced, but goodwill-heavy.
• Buying back shares? Yes — ~$2–3B/yr, share count −9% over four years, at good prices ($280–320 in 2025).
• Issuing shares to insiders? SBC is modest (~$276M, ~0.14% of revenue); not a dilution problem.
• Compensation policy? Bonus = 50% Adjusted Net Income / 20% Operating Revenue / 30% strategic; PSUs on Adjusted EPS + Operating Revenue. No ROIC or relative-TSR gate — a governance weakness. Say-on-pay ~92%. CEO comp $22.6M.
• Management motivations? Insider ownership is thin (<0.4%), but the 2025–26 open-market buying by the CEO (~$2.44M) and two directors is a genuine alignment/conviction signal into the decline.

Valuation & Market Data

• ADR / MLP / K-1? No — ordinary US C-corp common stock (NYSE: ELV); no K-1.
• Dividend policy? ~$6.88/yr (2026), ~2.0% yield, ~22% adjusted payout, ~5%/yr growth — conservative and well-covered.
• How profitable? Thin-margin (net ~2.8%), mid-teens-ROE, low-double-digit-ROIC — currently cyclically depressed.
• Net income diverging from cash from operations? Yes — materially, and this is the key flag. FY25 CFO ($4.29B) was only ~0.76x net income ($5.66B), down from ~1.0x+ historically, on a $2.5B receivable build and the BCBS settlement payment. The divergence must reverse for the recovery to be “real.”

Risks & Downside

• What would cause the stock to decline? A third guidance cut (2026 not the trough); CFO/NI staying broken; Medicaid/ACA morbidity overshooting pricing; a Carelon goodwill impairment; escalation of the “CMS matter”; medical-cost-trend re-acceleration.
• Catastrophic loss risk? Low — sound investment-grade balance sheet (A−/BBB+/Baa2), ~2.5x RBC, $37B investments, 42% debt/cap.
• Total loss risk? Negligible — a profitable, scaled, well-capitalized regulated insurer; bankruptcy is not a realistic scenario.

Recent News & Events

• Environment changed recently? Yes — the 2024–25 MLR reset, Medicaid redeterminations (complete 12/31/2025), the ACA enhanced-subsidy expiration (end-2025), and OBBBA (signed 7/4/2025, redetermination/work-requirement mandates from 2027–28).
• Significant acquisitions? CareBridge (Dec 2024) the largest; 2025 was a digestion pause ($88M).
• Accounting-policy changes? 2023 four-segment realignment (Health Benefits / CarelonRx / Carelon Services / Corporate); no material accounting-principle change.
• Other recent changes? Carelon President Haytaian departing (May 2026); two new independent directors (Collis, Schulman); FY2026 guidance raised at Q1 (adjusted ≥$26.75) but GAAP cut to ≥$19.85 (June 2026) on rising add-backs; Mizuho PT raised to $465 (June 2026).

APPENDIX B — Source Appendix

Elevance Health, Inc. (NYSE: ELV) · Report date 2026-06-13

All primary financial figures reconcile to SEC filings (EDGAR XBRL) and the trailing 5-year SEC filing corpus. Third-party market-data and news feeds are used as quantitative cross-checks and are reconciled to filings; any AI sentiment/scoring layers are treated as signals, not evidence.

Primary sources — SEC filings (EDGAR, CIK 0001156039)

Earnings-call transcripts (company IR; cross-checked to filings)

Third-party quantitative data (cross-check, reconciled to filings)

Peer public-filing cross-read (managed-care comps)

External / regulatory context

• KFF — Medicare Advantage enrollment & penetration data (industry framing).
• CMS — CY2026/CY2027 MA rate notices; Medicaid redetermination guidance.
• OBBBA (One Big Beautiful Bill Act, signed 2025-07-04) — Medicaid redetermination/work-requirement provisions (per 10-K disclosure).
• BCBS Association antitrust settlement (industry $2.8B; ELV $666M cash, paid Sept 2025) — per 10-K.

Fact/Interpretation/Assumption labels are applied inline. Management commentary (transcripts, guidance) is treated as hypothesis and validated against filings and financials.